385 related articles for article (PubMed ID: 26384681)
21. Influence of
Olthof SC; Forschner A; Martus P; Garbe C; Nikolaou K; la Fougère C; Gückel B; Vach W; Pfannenberg C
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2313-2321. PubMed ID: 32123968
[TBL] [Abstract][Full Text] [Related]
22. The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma.
Twycross SH; Burger H; Holness J
S Afr J Surg; 2019 Sep; 57(3):44-49. PubMed ID: 31392864
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
24. [Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography/ computed tomography for N-and M-staging of malignant melanoma].
Gu H; Xu W; Song X; Dai D; Zhu L; Wang J
Zhonghua Yi Xue Za Zhi; 2014 May; 94(17):1309-12. PubMed ID: 25142850
[TBL] [Abstract][Full Text] [Related]
25. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
Piccardo A; Foppiani L; Morbelli S; Bianchi P; Barbera F; Biscaldi E; Altrinetti V; Villavecchia G; Cabria M
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
[TBL] [Abstract][Full Text] [Related]
26. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V
Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
[TBL] [Abstract][Full Text] [Related]
27. Commentary on "Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle." Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam Hospital, Amsterdam, The Netherlands.: BJU Int 2013; 112(6):72934. doi:10.1111/bju.12109. [Epub 2013 Jun 24].
See WA
Urol Oncol; 2014 Nov; 32(8):1350. PubMed ID: 25488385
[TBL] [Abstract][Full Text] [Related]
28. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG-PET/CT in the Staging and Management of Melanoma: A Prospective Multicenter Ontario PET Registry Study.
Singnurkar A; Wang J; Joshua AM; Langer DL; Metser U
Clin Nucl Med; 2016 Mar; 41(3):189-93. PubMed ID: 26447374
[TBL] [Abstract][Full Text] [Related]
30. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma.
Falk MS; Truitt AK; Coakley FV; Kashani-Sabet M; Hawkins RA; Franc B
Nucl Med Commun; 2007 Apr; 28(4):273-80. PubMed ID: 17325590
[TBL] [Abstract][Full Text] [Related]
31. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM
Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDG PET/CT is useful in initial staging, restaging for pediatric rhabdomyosarcoma.
Dong Y; Zhang X; Wang S; Chen S; Ma C
Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):438-446. PubMed ID: 25996974
[TBL] [Abstract][Full Text] [Related]
33. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
34. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
36. Utility of 18F-FDG PET/CT in the diagnosis and staging of extramammary Paget's disease.
Tian Y; Wu HB; Li DL; Li HS; Zhou WL; Wang QS
Nucl Med Commun; 2015 Sep; 36(9):892-7. PubMed ID: 25932540
[TBL] [Abstract][Full Text] [Related]
37. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
38. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
[TBL] [Abstract][Full Text] [Related]
39. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
Groheux D; Giacchetti S; Delord M; de Roquancourt A; Merlet P; Hamy AS; Espié M; Hindié E
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):377-85. PubMed ID: 25432784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]